Atlas Trials

Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer

Clinical trial NCT02558868 · COMPLETED

Trial details

NCT number
NCT02558868
Sponsor
Zhejiang University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Neoplasms
Start date
2015-09-01
Primary completion
2017-09-30
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.